$BCLI to Provide Update on the Phase 3 Pivotal Trial of Autologous MSCNTF Cellular Therapy NurOwn in ALS Friday January 11 5PM ET httpsglobenewswire.comnewsrelease2019011116903010enBrainStormtoPresentNurOwnPhase3StudyUpdateatth

$BCLI to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS Friday January 11, 5PM ET https://globenewswire.com/news-release/2019/01/11/1690301/0/en/BrainStorm-to-Present-NurOwn-Phase-3-Study-Update-at-th

03:51 EST 11 Jan 2019 | Odi Bruckman

$BCLI to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS Friday January 11, 5PM ET https://globenewswire.com/news-release/2019/01/11/1690301/0/en/BrainStorm-to-Present-NurOwn-Phase-3-Study-Update-at-the-9th-Annual-California-ALS-Research-Summit-in-Irvine-CA.html …

More From BioPortfolio on "$BCLI to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS Friday January 11, 5PM ET https://globenewswire.com/news-release/2019/01/11/1690301/0/en/BrainStorm-to-Present-NurOwn-Phase-3-Study-Update-at-th"